Member Info for D-Geeman

'so why pay in shares if a deal is imminent'

If it isn't a *signed* deal then buyer could walk away or try to renegotiate. By then the money has left the bank acc. and AVCT is in a worse position in negotiations?

BTW and without wishing to cross-ramp Viking, it's damp squib not damp squid.

'Most of my Chinese is targeted at my new Hugo boss jumper

Mrs fuming'

Do you mean Mrs Fu-Ming?

Almost wish I'd bought Tempus shares rather than AVCT on reading these posts..

And last extract:

'All patients had either stabilized or improved on treatment with foralumab, and no patients have declined in key clinical measures. Additionally, 70% of these patients had seen a measurable improvement in fatigue. These data were the first to combine PET imaging with a novel ligand, immune-biomarkers, clinical measures and comprehensive safety data endpoints in patients receiving long-term intranasal foralumab. Patients not eligible for the Phase 2a trial may now be considered for this expanded EA program.

Tiziana also announced for the first time, quantitative data showing improvement in White Matter Z-scores measured from PET images taken at 3 months in nasal foralumab treated patients with non-active secondary progressive multiple sclerosis (na-SPMS). White Matter Z-scores are a statistical measure used in neuroimaging studies to assess the integrity or abnormalities in structures of the brain.

In May:

Tiziana announced it had submitted an FDA request to obtain Orphan Drug Designation for intranasal foralumab for the treatment of non-active secondary progressive Multiple Sclerosis (na-SPMS). This request would make foralumab the first therapy for na-SPMS to receive Orphan Drug Designation. Our request is supported by clinical and non-clinical evidence of foralumab’s effectiveness in na-SPMS. The prevalence estimates, in part, are supported from the Brigham & Women’s Hospital, Boston, Massachusetts, longitudinal study, the CLIMB data of which allowed the estimate of na-SPMS in the population. The FDA have requested further information from Tiziana with regards to this request.'

The oral presentation, delivered by Tarun Singhal, M.B.B.S., M.D., Director of the PET Imaging Program in Neurologic Diseases at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System, and Associate Professor of Neurology at Harvard Medical School, assessed the effect of intranasal foralumab on microglial activation in na-SPMS patients with PIRA as measured by positron emission tomography (PET) imaging via [F-18]PBR06-PET, a novel, long-half-life ligand used in PET scanning. The study is designed to be open-label and part of the Expanded-Access Program evaluating foralumab in na-SPMS patients that is currently underway.

Five of six patients (83%, 95% confidence interval 44%-97%) showed a qualitative reduction on [F-18]PBR06-PET in multiple brain regions after both 3 and 6 months of nasal foralumab treatment, which implies that there is in vivo evidence for reduced microglial activation and neuroinflammation following treatment with nasal foralumab. White matter z-scores (a measure of abnormally increased neuroinflammation) were reduced by 26-36% in the foralumab-treated group at 3 and 6 months, which was >4-5-times higher compared to 6% variability in the test-retest group. Clinically, foralumab-treated patients demonstrated a stable EDSS and improvement in the Modified Fatigue Impact Scale (MFIS). Reduction in fatigue as measured by the MFIS is clinically relevant to the lives of na-SPMS patients and will be a key monitoring parameter moving forward.

Nasal foralumab attenuated microglial activation in na-SPMS patients with PIRA at 3 and 6 months, as evaluated by [F-18]PBR06-PET and was associated with clinical symptom stability. Based on these positive results, a double-blind, placebo-controlled, dose-ranging study of nasal-foralumab in na-SPMS with [F-18]PBR06-PET as a primary endpoint with measures of EDSS and MFIS is underway. This trial (NCT06292923) is important because if the potential to slow disease progression is demonstrated this would align with early treatment intervention.

Tiziana announced additional positive clinical results from its intermediate sized Expanded Access Program (EAP) for non-active secondary progressive multiple sclerosis (na-SPMS) patients. The data demonstrated multiple improvements in foralumab-treated patients, with 70% showing an improvement in fatigue after six months of follow-up. Fatigue is a debilitating symptom for many MS patients and is measured by the Modified Fatigue Impact Scale (MFIS).

Tiziana also announced that the U.S. Food and Drug Administration (FDA) had allowed its intranasal foralumab non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access (EA) Program to expand from 10 patients to a total of 30 patients.

Up until April, of the 10 participating patients, two patients had been dosed for more than one year and eight additional patients had been dosed for six months, all without serious side effects. All patients had

And (sorry) moving to the correct thread :-/

'vascular inflammation associated with Type 2 Diabetes (T2D) and also in a separate population of patients with non T2D obesity.

Tiziana announced that positive findings had been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients. These patients had shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS). PET scan findings showing a reduction in microglial activation were also seen in the six patients with MFIS score improvement at the three-month evaluation period.

In April:

Tiziana announced a platform presentation titled, “Treatment of PIRA with Nasal Foralumab Dampens Microglial Activation and Stabilizes Clinical Progression in Non-Active Secondary Progressive MS” at the Annual Meeting of the American Academy of Neurology in Denver, Colorado. The presentation included new, encouraging quantitative imaging data from foralumab’s intermediate-size patient population Expanded Access Program. In the presentation, foralumab, a fully human anti-CD3 monoclonal-antibody showed the attenuation of microglial activation in patients with non-active secondary progressive multiple sclerosis (na-SPMS) based on positron emission tomography (PET) imaging and disease stabilization in na-SPMS patients with disease progression independent of relapse (PIRA).'

Https://ir.tizianalifesciences.com/node/11551/html

Buried at the bottom:

'In May:

Tiziana announced it had submitted an FDA request to obtain Orphan Drug Designation for intranasal foralumab for the treatment of non-active secondary progressive Multiple Sclerosis (na-SPMS). This request would make foralumab the first therapy for na-SPMS to receive Orphan Drug Designation. Our request is supported by clinical and non-clinical evidence of foralumab’s effectiveness in na-SPMS. The prevalence estimates, in part, are supported from the Brigham & Women’s Hospital, Boston, Massachusetts, longitudinal study, the CLIMB data of which allowed the estimate of na-SPMS in the population. The FDA have requested further information from Tiziana with regards to this request.'

From the start:

'NEW YORK, October 18, 2024 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced interim financial results for the six months ended June 30, 2024, and provided a corporate update on its lead programs in development.

Gabriele Cerrone, Executive Chairman, and founder of Tiziana, commented, “The past six months have been defined by meaningful strides in advancing our portfolio of innovative therapeutic candidates. In particular, we are encouraged by the progress in our lead programs targeting neurodegenerative and autoimmune diseases. Our lead asset, foralumab, continues to show significant promise in our expanded access program for multiple sclerosis (MS), which has reaffirmed our confidence in its potential to revolutionize treatments in this area.

We have also achieved a key milestone in our intranasal formulation of foralumab, the start of our Phase 2 study for non-active (non-relapsing) Secondary Progressive Multiple Sclerosis. The positive early-stage clinical data from our expanded access Multiple Sclerosis studies have been very encouraging, indicating the potential of our novel approach to delivering therapies with increased efficacy and fewer side effects compared to traditional treatments. As we continue to evaluate these outcomes, we are optimistic that this can offer patients a much-needed, more tolerable option for managing chronic conditions.

We have been awarded Fast Track designation by the FDA, which is a significant milestone, providing an expedited review process and increased interaction with the FDA. This designation is intended to facilitate the development of and expedite the review of drugs that treat serious conditions and fill an unmet medical need.”

First Half 2024 Developments Related to Foralumab

In January:

Tiziana announced the filing of a new patent application relating to composition and methods for combining GLP-1ra and foralumab, a fully human anti-CD3 antibody, to achieve further reductions in systemic and vascular inflammation associated

Sorry for sending flak your way Bella.

Obviously think that someone who might still be alive in 4 years' time and with prostate cancer ('FAP is overexpressed in metastatic tumors and is present in all primary prostatic carcinomas') was an utterly bonkers thing to post on a site where we often discuss AVA6k; a drug which targets FAP.

‘ High levels of fibroblast activation protein (FAP) in prostate cancer are associated with an aggressive disease, increased risk of lymph node metastasis, and decreased overall survival:

Expression: FAP is a transmembrane serine protease that's normally expressed during development and at sites of tissue remodeling. In prostate cancer, FAP is overexpressed in metastatic tumors and is present in all primary prostatic carcinomas.’

‘Sir Chris Hoy performed the baton ceremony before the men's cycling sprint finals at this year's Paris Olympics

Published

19 October 2024, 22:49 BST

Updated 46 minutes ago

Six-time Olympic cycling champion Sir Chris Hoy has announced that his cancer is terminal.

In an interview with the Sunday Times,, external he says doctors have told him he has between two and four years to live.

The 48-year-old Scot revealed earlier this year that he had been diagnosed with cancer.

Hoy told the newspaper he has known for a year that his cancer is terminal.

Hoy won six Olympic golds between 2004 and 2012 - the second highest total by any British Olympian behind Sir Jason Kenny's tally of seven.

He retired from cycling in 2013 and in recent years has been a regular pundit and commentator as part of BBC Sport's cycling coverage.

He had not previously disclosed the type of cancer.

But he told the Sunday Times that he had been diagnosed with primary cancer in his prostate, which had spread to his bones - meaning it was stage four.

Tumours were discovered to his shoulder, pelvis, hip, spine and rib.

Sir Chris told the newspaper: "As unnatural as it feels, this is nature.

"You know, we were all born and we all die, and this is just part of the process.‘

'close you’re short mate ‘

Do you know the difference between ‘you’re’ and ‘your’ Watching? It’s a mistake you repeatedly make so I doubt you do.

When I copied your posts last night it didn’t take long to find plenty of howlers. But what struck me is that, however far one goes back, there’s not a single post that gives any insight on Avacta or the occasional other company you post on. Zero insight or original thought. Just clown emoticon in the main, and nonsense statements.

Are you proud of that record?

I don’t have much insight myself (compared to others on here) but at least I’ve had the odd original idea. But you, nothing. Zero.

'But a what sort of sp will this hit before that !' asked at Price: 64.00

Well, since you asked Watching2, 60p for starters. The curse of Watching2..

You got 11 Recs and I now think people actually Rec you to take the Mickey. I'll be your 12th Rec.

'Don’t see that post being here when I wake up tomorrow': Perhaps not Touk!

But I am up early. Bin men in the morning and can't put the stuff out tonight or the foxes will rip it to shreds.

Have a good sleep!

DG

Some previous 'insights' from Watching2. Probably hard for you to get deleted at this time of night Watching?

'10 Oct 2024 08:22

Next rns they will be announcing a jv

No Opinion

RE: Tree Shake11 Jul 2024 10:06

Price: 82.25

Yep !

This is I’ll only going one way

Watching2

Posted in: AVCT

Posts: 8,212

Price: 44.25

No Opinion

RE: RNS26 Jun 2024 08:12

Will our regular Fudders every be seen again !

RE: Interesting.23 May 2024 08:49

Brilliant rns ! We are slowly becoming more attractive to big pharmas not long to wait now !'

And a few old(er) chestnuts from Watching:

No Opinion RE: Resistance 90/95p26 Feb 2024 08:45

No funding required till 2025

Watching2

Posted in: AVCT

Posts: 7,775

Price: 85.50

No Opinion

RE: Potential fund raise23 Feb 2024 14:36

Lone 🤡 no placing required we have plenty cash atm.

Nice try tho 🤣

Watching2

Posted in: AVCT

Posts: 7,775

Price: 111.50

No Opinion

RE: Festive cheer22 Dec 2023 15:29

Definitely won’t. Be here next We will be . Sold

£20 plus per share

All done n dusted

Merry Christmas

Ps I’m already looking for a company to put a bit of profit into 😊

Watching2

Posted in: AVCT

Posts: 7,775

Price: 139.00

No Opinion

RE: TRADING28 Nov 2023 09:14

That has always been the case,

I Agree selling now would be bonkers

Gl x

Well done Doggy. You've made a few quid and shown Watching ("Blink of a eye ") 2 up to be less than literate, if there's anyone who didn't know that by now.

I think people want you to make money but not on days when they lose money themselves; call it the Wyndrum effect if you like.

No, they were not free. They were spilt off from original Tils shares, so after splitting the Tils shares were worth less than before the split, dropping by an amount equal to the new value of the accustem shares (in theory anyway).

'initial public offering price of $9.90 per ADS' : they've never traded that high, 93 / 94 cents as I write, so it hasn't been a great success yet.

Bella, I forget all the details but they did use ADSs and ratio was 10:1 so the sp was high enough for the Nas. I also found a time when they were giving 1 new TLSA for 5 TILS shares.

This seems to be the best article on how they did it, in a quick search. https://www.businesswire.com/news/home/20181119005939/en/Tiziana-Announces-Pricing-of-Offering-and-Warrant-Conversion-Raising-in-Aggregate-5.79-million-of-New-Equity-Capital-Approval-to-List-on-the-Nasdaq-Global-Market-and-Loan-Conversion-Extinguishing-1.78-million-of-Debt

Thanks Bella

'Good to see that the BB police are out deleting posts they don’t like again'.

Coincides with Watching2's arrival, who posted this at 7.59:

'Watching2

Posted in: AVCT

Price: 61.50

No Opinion

RE: RNSToday 07:59

"Market will like this !" (– Curse of Watching2 strikes yet again).

Off topic I know but are there any landlords out there..

I found out about this today. https://www.gov.uk/guidance/property-alert It's a Land Registry alert system if someone enquires about your property and so helps stop the property theft tat sometimes happens with rental properties. Absolutely free, and so easy to use.

Or just use to see when your neighbours start to sell their house! You can list 10 properties you want to 'watch'.